Transcranial Direct Current Stimulation Market Size, Share, Industry, Forecast and outlook (2024-2031)

Report Overview

The Global Transcranial Direct Current Stimulation Market reached US$ 1,346.13 million in 2023 and is expected to reach US$ 2,741.88 million by 2031 growing with a CAGR of 9.3% during the forecast period 2024-2031.

Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that involves applying a low electric current to the scalp through electrodes. Typically, this current ranges from 1 to 2 mA. tDCS operates by delivering either a positive (anodal) or negative (cathodal) current, which modulates neuronal activity in targeted brain regions. The positioning of these electrodes determines how the current flows, allowing for specific areas of the brain to be stimulated.
 

The mechanism of tDCS does not involve generating action potentials in neurons; instead, it produces "sub-threshold" effects that enhance or inhibit the activity of already active neurons. This can be conceptualized as tDCS boosting ongoing brain activity related to tasks or learning processes. At the cellular level, tDCS influences neuronal firing and enhances synaptic transmission, thereby promoting synaptic plasticity, which is essential for learning.

tDCS is frequently utilized in conjunction with training activities, where the stimulation amplifies the learning effects produced by the training itself. Clinical applications being explored for tDCS include treatment for conditions such as depression, schizophrenia, aphasia, addiction, epilepsy, chronic pain (including migraines and fibromyalgia), attention disorders, and motor rehabilitation. Beyond medical uses, tDCS is also applied in non-clinical settings for purposes like accelerated learning, improved focus, relaxation, and meditation.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Increasing prevalence of neurological and psychiatric disorders

The demand for the global transcranial direct current stimulation (tDCS) market is driven by multiple factors. One of the key factors is the increasing prevalence of neurological and psychiatric disorders. The rising rates of mental health issues, including depression, anxiety, chronic pain, and cognitive impairments, have greatly impacted the expansion of the transcranial direct current stimulation (tDCS) market. tDCS is a non-invasive brain stimulation method that delivers a mild electrical current to targeted regions of the scalp, intending to influence neuronal activity and enhance neuroplasticity.

tDCS operates by modifying the excitability of neurons in specific areas of the brain. When anodal (positive) stimulation is applied, it can increase neuronal excitability, whereas cathodal (negative) stimulation can decrease it. This modulation can result in functional changes in the brain that are advantageous for treating a range of psychiatric and neurological conditions. A significant study published in the Lancet Neurology revealed that as of 2021, more than 3 billion individuals globally were affected by neurological conditions, which account for over 43% of the world's population.

Moreover, key players in the industry research activities, technological advancements, and product approvals would drive this market growth. For instance, as per HCPLive news in January 2024, a recent study has found that home-use transcranial direct current stimulation (tDCS), when combined with either a digital psychological intervention or a digital placebo, does not demonstrate superiority over sham treatment for individuals experiencing a major depressive episode. This conclusion comes from a well-structured clinical trial designed to assess the efficacy of these interventions.

Also, in a Healthcare Europe research publication in January 2024, self-administered brain stimulation, particularly through transcranial direct current stimulation (tDCS), is emerging as a novel tool for treating depression. This approach allows patients to manage their treatment at home, potentially increasing accessibility and convenience for those suffering from major depressive disorder (MDD).

Similarly, in May 2022, Flow Neuroscience announced that it had received full Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to conduct a pivotal trial in the United States using its self-managed transcranial direct current stimulation (tDCS) headset for the treatment of Major Depressive Disorder (MDD). This marks a significant step in making their innovative brain stimulation technology more accessible to patients suffering from depression.

Restraints

Factors such as regulatory challenges, the presence of alternative neuromodulation techniques,  and lack of awareness among individuals are expected to hamper the market.

Market Segment Analysis

The global transcranial direct current stimulation (tDCS) market is segmented based on device type, application, end-user, and region.

The 1*1 tDCS platform segment accounted for approximately 46.8% of the global transcranial direct current stimulation (tDCS) market share

The 1*1 tDCS platform segment is expected to hold the largest market share over the forecast period. The 1x1 tDCS platform developed by Soterix Medical is a leading device in the transcranial direct current stimulation (tDCS) market, known for its precision, reliability, and customization capabilities. This platform is designed for both clinical and research applications, offering a range of unique features that set it apart from other devices.

The platform features an Open-Panel interface that streamlines the setup process and facilitates straightforward monitoring of stimulation settings. Additionally, it utilizes advanced technologies like SmartSCAN, which provides real-time monitoring of electrode contact, and TrueCurrent, which guarantees consistent current delivery during the entire stimulation session.

The Soterix Medical 1x1 tDCS device represents a significant advancement in the field of transcranial direct current stimulation (tDCS), designed specifically for clinical research and therapeutic applications. Developed by a team of clinical researchers, scientists, and biomedical engineers, the 1x1 platform is recognized for its precision and reliability in delivering tDCS protocols.

The Soterix Medical 1x1 tDCS device is recognized as a premier solution in the neuromodulation field, particularly for research and clinical applications aimed at addressing mental health issues such as depression. Its design combines user-friendly features with advanced technology and adaptability, making it an essential instrument for researchers who wish to investigate the therapeutic benefits of tDCS while ensuring safety and consistency in their studies. Consequently, it has established itself as the benchmark for accurate and reproducible tDCS in clinical trials, contributing to the advancement of knowledge regarding brain stimulation therapies.

Market Geographical Analysis

North America accounted for approximately 43.2% of the global transcranial direct current stimulation (tDCS) market share

North America region is expected to hold the largest market share over the forecast period owing to the growing prevalence of neurological and psychiatric disorders, including depression, anxiety, and chronic pain, which is a major factor driving the expansion of the transcranial direct current stimulation (tDCS) market. 

There is an increasing recognition and acceptance of non-invasive treatment options among healthcare professionals and patients alike. This trend is fueling the adoption of tDCS devices in clinical settings as a viable alternative to conventional pharmacological therapies. Moreover, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, rising demand for home-use devices, innovative technological advancements, government initiatives, and ongoing research studies, product launches & approvals would propel this market growth. 

For instance, in  April 2022, the Florida State University College of Nursing launched the Brain Science and Symptom Management Center (BSSMC), an institute focused on interdisciplinary research to optimize pain and symptom management using brain stimulation and computer technology. The center is led by Dr. Hyochol "Brian" Ahn, who has received significant funding from the National Institutes of Health (NIH) to explore the use of transcranial direct current stimulation (tDCS) in combination with mindfulness-based meditation for self-management of clinical pain and symptoms in older adults with knee osteoarthritis.

Also, in March 2023, Sooma Medical received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its portable, patient-administered neuromodulation device aimed at treating depression. This designation is granted to innovative therapies that show significant potential to improve treatment options for severe or life-threatening conditions. 

Market Segmentation

By Device Type

• Depression LTE System
• 1*1 tDCS Platform
• Thebraindriver v2.1 Deluxe System
• DC-Stimulator Mobile
• Nurostym Transcranial Electrical Stimulation (tES)
• Others

By Application

• Depression
• Anxiety
• Chronic Pain
• Cognitive Impairments

By End-User

• Hospitals & Home Use
• Neurological Clinics
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • The rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major global players in the transcranial direct current stimulation (tDCS) market include Soterix Medical Inc., TheBrainDriver, LLC.,  Neurocare group AG, Brainbox Ltd, BrainsWay, Magstim, eNeura Inc., MagVenture A/S, Nexalin Technology, and RPW Technology, LLC among others.

Key Developments

• In September 2024, the medical-grade neurotechnology wearable for premenstrual syndrome (PMS) refers to an innovative device designed to provide a drug-free solution for managing PMS and menstrual pain. This wearable, developed by the startup Samphire Neuroscience and named Nettle, utilizes transcranial direct current stimulation (tDCS) to target specific areas of the brain associated with mood regulation and pain perception.
• In April 2024, Neurovalens, a Belfast-based neurotech startup, received FDA clearance for its Modius Stress device, a non-invasive home-use neurostimulation system designed to treat generalized anxiety disorder (GAD).

Why Purchase the Report?

• To visualize the global transcranial direct current stimulation (tDCS) market segmentation based on device type, application, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points on the transcranial direct current stimulation (tDCS) market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel with key products of all the major players.

The global transcranial direct current stimulation (tDCS) market report would provide approximately 62 tables, 57 figures, and 183 pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies